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Editorial on the Research Topic
Novel Cancer Treatments based on Autophagy Modulation
Autophagy is an intracellular process in response to stimulus by which damaged organelles, protein
aggregates, or invading pathogens, are targeted from autophagic vesicles to lysosomes and then
eliminated (Mizushima et al., 2011). Autophagy has been described to play a role in several
pathological conditions, including neurodegenerative disorders, infectious diseases, and cancer.
The role of autophagy in cancer remains highly controversial, and it is likely reliant on the tumor
type, the stage of neoplasia, the cellular context, as well as on the metabolic context in which the cells
lie. Earliest reports suggested a role of autophagy against tumorigenesis favoring tumor cell death in
an apoptotic-dependent or independent way (Levine and Yuan, 2005; Pattingre et al., 2005). In this
regard, uncontrolled autophagy can lead to excessive degradation of cellular constituents and
organelles required for the cells’ homeostasis, and its enhancement represent a valid therapeutic
target of many anticancer drugs. Hence, autophagy has been widely known as a tumor-suppressive
mechanism and cancer cells with limited autophagy may suffer from increased oxidative stress, DNA
damage, and genomic instability, which lead to the acquisition of genome mutations that drive
tumorigenesis (Mathew et al., 2007; Mathew et al., 2009). On the other hand, autophagy also plays a
protective role in cancer cells by removing damaged organelles or recycling misfolded
macromolecules. Several studies report that autophagy tries to satisfy the high metabolic
demands of the proliferating tumor cells suffering stressful conditions, such as nutrient
deprivation, oxidative stress, hypoxia, or in response to therapy (Condo et al., 2005).
Hence, the possibility to modulate autophagy may represent a useful therapeutic approach to treat
different types of cancer. In this regard, a variety of clinical trials based on autophagy modulators are
ongoing. For instance, in tumors with enhanced autophagy, which acts as a survival mechanism and
chemoresistance, its inhibition can make them more prone to initiate cell death mechanisms. In this
sense, there are a variety of examples showing that autophagy inhibitors, as 3-methyl-adenine (3-
MA) or hydroxychloroquine (HCQ), when used in combination with anticancer drugs, may sensitize
chemoresistant cells, thus leading to cancer cell death (Jain et al., 2013; Lee et al., 2015). However,
excessive autophagy induction upon cytotoxic drug treatments or through the use of autophagy
inducers, as mTOR inhibitors, may also lead to autophagic cell death (Bursch et al., 1996; Tian et al.,
2019).
On the other hand, recent advances in nanomedicine make it possible to fight cancer with effective
therapeutic compounds, removing the obstacles encountered with traditional drugs. Interestingly,
nanomaterials have been explored as potent modulators of autophagy through multiple mechanisms
and have been exploited as therapeutic agents against cancer (Cordani and Somoza, 2019). For this
reason, autophagy modulation with chemotherapy drugs, including nanoparticle-based strategies,
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would acquire clinical relevance in the near future, as a
complementary therapy for the treatment of cancers.
This Research Topic gathers original research and review
papers on novel drugs and nanomaterials in cancer treatment
based on autophagy modulation and the related molecular
mechanisms of action ranging from basic research to more
applied translational and clinical studies. The 17 accepted
articles consist of 9 Original Research articles and 8 Reviews
or Mini-Reviews, demonstrating that inhibition or enhancement
of the autophagy pathway may serve as an effective tool to
counteract cancer.
Some of the research articles published describe the anticancer
proprieties, both in vivo and in vitro, of several natural substances
by modulating signaling pathways regulating autophagy in
various tumors, thus representing great candidates for further
therapeutic applications. Wang et al. showed that Sotetsuflavone,
a naturally derived and occurring flavonoid, induced autophagy
in lung cancer blocking PI3K/Akt/mTOR signaling pathway in
vivo and in vitro, was able to increase the levels of pro-apoptotic
markers, as cytochrome C or cleaved-caspase 3, and to reduce the
expression of cyclin D1 and CDK4, thus blocking cell cycle in the
G0/G1 phases. Tsai et al. reported that 6-Gingerol, a natural
phenol found in ginger, inhibits lung cancer cell growth via
suppression of USP14 expression and enhances autophagy-
dependent ferroptosis, revealing the therapeutic efficacy of 6-
Gingerol in A549 and its possible mechanism of action.
Natural compounds derived from herbal medicines have been
extensively studied for their anticancer proprieties through
modulation of signaling pathways leading to tumor cell death
in various cancer types. In this context, Wu et colleagues showed
that honokiol and magnolol, two compounds derived by
magnolia bark extract, display therapeutic potential causing
cell cycle arrest, induction of caspase 3-dependent apoptosis,
and autophagy in high-grade urothelial carcinoma. Chen et al.
explored the anti-breast cancer potential of ethanol crude extracts
from Brucea javanica seed (BJE). Their data showed that BJE
could inhibit breast cancer cell proliferation and induce
apoptosis, together with the inhibition of autophagy, as
demonstrated by the reduction of several autophagy-related
markers and the increase of mTOR phosphorylation. Gao
et al. revealed the molecular mechanisms through, which
Moracin N (MAN), a secondary metabolite extracted from the
leaves of Morus alba L, inhibited cell proliferation and induced
apoptosis in lung cancer cells. Interestingly, they found thatMAN
treatment dysregulated mitochondrial function and enhanced
autophagy flux, concomitantly to the inhibition of mTOR
signaling pathway in a time- and dose-dependent manner.
Defects in autophagy lead to the accumulation of impaired
mitochondria, which are a potential source of ROS that lead to
DNA damage and genomic instability. In this regard, Chicote
et al. reported that autophagy inhibitor 3-methyladenine
displayed cytotoxicity in mouse fibroblasts and correlates with
massive DNA damage, suggesting that in growing conditions,
autophagy acts as a protective mechanism to diminish the
intrinsic cytotoxicity of 3-methyladenine.
Recently, it has been shown that platinum compounds exert
long-term effects, including autophagy activation in rat B50
neuroblastoma cells (Grimaldi et al., 2019). However, although
cancer therapy based on platinum compounds display a potent
anticancer effect, it also causes many side effects that limit its
applicability. In this regard, Zhang et al. showed here that drug-
induced platinum accumulation might also interfere with
immune cells and, thus, increase the risk of immune toxicity
in cancer patients.
However, due to their ability to elicit autophagy, metal-based
compounds remain attractive agents for anticancer applications.
Here, Chen et al. showed that nickel complex NiPT, a
proteasomal inhibitor, was able to induce autophagy by
dysregulating AMPK/mTOR signaling pathways in both
cultured tumor cell lines and cancer cells derived from acute
myeloid leukemia human patients. Interestingly, they found that
NiPT leads to apoptosis in lung cancer cells if it is concomitantly
used together with autophagy inhibitors, suggesting that NiPT-
induced autophagy protects cancer cells from death.
The Research Topic also counts with several well-structured
review articles that summarize studies describing novel drugs and
nanomaterials in cancer treatment based on autophagy
modulation and the related molecular mechanisms.
In recent years, several nanocarriers have been developed and
investigated to improve the solubility, bioavailability, controlled
release of therapeutics, and increase their cytotoxic effect on
cancer cells. Sharma et al. highlighted that the use of
nanoparticles for the delivery of miRNA-34a in cancer cells
might inhibit critical autophagy-related pathways, thus
sensitizing cancer cells to traditional chemotherapy drugs. On
the other side, Condello et al. focused on the most effective
liposomal formulations for the simultaneous transport of
chemotherapeutics and autophagy inhibitors to control
pharmacokinetics and targeting, thus reducing the adverse
effects of drugs.
Alkylphosphocholine (APC) derivatives represent a novel
class of antineoplastic agents that inhibit the serine–threonine
kinase Akt, which acts as the primary regulator of cell survival.
Berger et colleagues focused their attention on the capability of
such structures to induce autophagy by inhibiting the Akt/mTOR
cascade when administered as monotherapy or in combination
with other drugs.
The cytoprotective role that autophagy plays under certain
conditions during cancer therapy is well assumed, and many
studies have been addressed to reduce protective autophagy to
overcome drug resistance in the clinical practice. Liu et al.
discussed the advantages of combining agents that induce
cytoprotective autophagy with autophagy inhibitors as a
cancer therapeutic approach in clinical application. Hence, the
exploitation of appropriate autophagy might cooperate with
traditional anticancer drugs to overcome drug resistance.
Iron-dependent ferroptosis is a type of cell death discovered in
recent years, which is driven by lipid peroxidation and, recently, it
has been linked with various kinds of diseases, including cancer.
Lin et al. elegantly described the relationship between ferroptosis
and autophagy and focused their interest on small molecules
inducing ferroptosis, which have been observed to lead to a robust
inhibitory effect on tumor growth and enhance the sensitivity to
chemotherapeutic drugs. The tripartite motif family of proteins
Frontiers in Pharmacology | www.frontiersin.org April 2021 | Volume 12 | Article 6505592
Cordani et al. Editorial: Autophagy Modulation for CancerTherapy
(TRIMs) has emerged as a critical regulator of the autophagy
process, and their dysregulation is strongly connected to
oncogenesis or cancer progression. The review of Mandell
et al. covers how the actions of TRIM proteins intersect with
and orchestrate autophagy, thus contributing to cancer
progression and the possibility of targeting TRIM-directed
autophagy in cancer therapy.
Recently, the interest in metabolic therapy for cancer has
been renewed, particularly in amino acid deprivation by
enzymes. In this context, L-asparaginase was approved for
the treatment of acute lymphoblastic leukemia by the U.S.
Food and Drug Administration (Truelove et al., 2013).
Importantly, the combination of amino acid degrading
enzymes and autophagy regulators has been demonstrated
to show synergistic anticancer effects in preclinical and
clinical studies (Song et al., 2015). In this sense, Wang et al.
highlighted recent advances of several potential anticancer
enzymes and the concomitant employment of autophagy
modulators with amino acid degrading enzymes as potential
cancer therapeutic approaches.
Recent studies have elucidated that autophagy, in addition to
lead severe metabolic changes and chemoresistance also plays a
role in regulating the immune system, and increasing attention
has been focused on the potential applications of autophagy
modulation for tumor immunotherapy. In this regard, Lim
and Murthy summarized their current understanding of how
autophagy drives tumor progression and chemoresistance via
immunosuppression and they resumed an increasing set of
pharmacologically actionable targets in the autophagy
pathway, which may serve for novel cancer immunotherapies.
In conclusion, this collection of Review and Original Research
articles critically summarizes the current understanding of how
autophagy modulation could be exploited for cancer treatment.
We believe that these advances will inspire basic and clinical
scientists working in related fields to investigate molecular
mechanisms and translational studies further.
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